In today’s episode, the discussion features Surbhi Sidana, MD, an associate professor of medicine (blood and marrow transplantation and cellular therapy) and leader of the Myeloma CAR-T/Immunotherapy Program at Stanford University/Stanford Medicine, as well as a member of the Stanford Cancer Institute, who provided clinical and regulatory perspectives on the FDA approval of belantamab mafodotin-blmf (Blenrep) in combination with bortezomib (Velcade) and dexamethasone (BVd) for adult patients with relapsed or refractory multiple myeloma who have received at least 2 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent. The approval was supported by findings from the phase 3 DREAMM-7 trial (NCT04246047).
All content for OncLive® On Air is the property of OncLive® On Air and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In today’s episode, the discussion features Surbhi Sidana, MD, an associate professor of medicine (blood and marrow transplantation and cellular therapy) and leader of the Myeloma CAR-T/Immunotherapy Program at Stanford University/Stanford Medicine, as well as a member of the Stanford Cancer Institute, who provided clinical and regulatory perspectives on the FDA approval of belantamab mafodotin-blmf (Blenrep) in combination with bortezomib (Velcade) and dexamethasone (BVd) for adult patients with relapsed or refractory multiple myeloma who have received at least 2 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent. The approval was supported by findings from the phase 3 DREAMM-7 trial (NCT04246047).
S14 Ep57: Cevostamab-Based Regimens Usher In the Next Wave of Bispecific Antibody Strategies in R/R Myeloma: With Joshua Richter, MD
OncLive® On Air
6 minutes
1 month ago
S14 Ep57: Cevostamab-Based Regimens Usher In the Next Wave of Bispecific Antibody Strategies in R/R Myeloma: With Joshua Richter, MD
Dr Richter discusses the rationale for targeting FcRH5 in myeloma and the evaluation of cevostamab-based combination strategies in this disease.
OncLive® On Air
In today’s episode, the discussion features Surbhi Sidana, MD, an associate professor of medicine (blood and marrow transplantation and cellular therapy) and leader of the Myeloma CAR-T/Immunotherapy Program at Stanford University/Stanford Medicine, as well as a member of the Stanford Cancer Institute, who provided clinical and regulatory perspectives on the FDA approval of belantamab mafodotin-blmf (Blenrep) in combination with bortezomib (Velcade) and dexamethasone (BVd) for adult patients with relapsed or refractory multiple myeloma who have received at least 2 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent. The approval was supported by findings from the phase 3 DREAMM-7 trial (NCT04246047).
